WO2014173905A3 - Methods and kits for prognosis of stage i nsclc by determining the methylation pattern of cpg dinucleotides - Google Patents

Methods and kits for prognosis of stage i nsclc by determining the methylation pattern of cpg dinucleotides Download PDF

Info

Publication number
WO2014173905A3
WO2014173905A3 PCT/EP2014/058150 EP2014058150W WO2014173905A3 WO 2014173905 A3 WO2014173905 A3 WO 2014173905A3 EP 2014058150 W EP2014058150 W EP 2014058150W WO 2014173905 A3 WO2014173905 A3 WO 2014173905A3
Authority
WO
WIPO (PCT)
Prior art keywords
prognosis
stage
methylation pattern
nsclc
determining
Prior art date
Application number
PCT/EP2014/058150
Other languages
French (fr)
Other versions
WO2014173905A2 (en
Inventor
Manel Esteller Badosa
Juan SANDOVAL DEL AMOR
Jesús MÉNDEZ GONZÁLEZ
Original Assignee
Institut D'investigació Biomèdica De Bellvitge (Idibell)
Fundació Institució Catalana De Recerca I Estudis Avançats
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut D'investigació Biomèdica De Bellvitge (Idibell), Fundació Institució Catalana De Recerca I Estudis Avançats filed Critical Institut D'investigació Biomèdica De Bellvitge (Idibell)
Publication of WO2014173905A2 publication Critical patent/WO2014173905A2/en
Publication of WO2014173905A3 publication Critical patent/WO2014173905A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Abstract

The present invention relates to the field of pharmacogenomics and in particular to an in vitromethod for prognosis of a stage I NSCLC patient, comprising determining in a biological sample of said patient the methylation pattern in one or more genes. It further relates to an in vitromethod for selecting a stage I NSCLC patient for an anti-cancer treatment based on the method of prognosis. Also, it relates to nucleic acids and kits useful for these methods and an anti-cancer treatment for the selected patients. In some preferred aspects, the methylation pattern is determined in at least one gene selected from the group of PCDHGB6, HIST1H4F, NPBWR1, ALX1, and HOXA9.
PCT/EP2014/058150 2013-04-23 2014-04-22 Methods and kits for prognosis of stage i nsclc by determining the methylation pattern of cpg dinucleotides WO2014173905A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13382147.0 2013-04-23
EP13382147 2013-04-23
EP13185321.0 2013-09-20
EP13185321 2013-09-20

Publications (2)

Publication Number Publication Date
WO2014173905A2 WO2014173905A2 (en) 2014-10-30
WO2014173905A3 true WO2014173905A3 (en) 2015-04-23

Family

ID=50680012

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/058150 WO2014173905A2 (en) 2013-04-23 2014-04-22 Methods and kits for prognosis of stage i nsclc by determining the methylation pattern of cpg dinucleotides

Country Status (1)

Country Link
WO (1) WO2014173905A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3190191A1 (en) * 2016-01-11 2017-07-12 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Method and kit for the diagnosis of lung cancer
CN108913777B (en) * 2018-08-16 2022-10-18 上海市公共卫生临床中心 DNA methylation related marker for diagnosing tumor and application thereof
CN110964811B (en) * 2018-09-29 2022-04-29 广州康立明生物科技股份有限公司 HOXA9 methylation detection reagent
WO2022187246A1 (en) * 2021-03-01 2022-09-09 National Taiwan University Method and kit for monitoring non-small cell lung cancer
CN113652490B (en) * 2021-09-27 2022-07-22 广州凯普医药科技有限公司 Primer probe combination and kit for early screening and/or prognosis monitoring of bladder cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044331A2 (en) * 2000-11-29 2002-06-06 Cangen International Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer
WO2008063655A2 (en) * 2006-11-20 2008-05-29 The Johns Hopkins University Dna methylation markers and methods of use
WO2012175562A2 (en) * 2011-06-21 2012-12-27 University Of Tartu Methylation and microrna markers of early-stage non-small cell lung cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044331A2 (en) * 2000-11-29 2002-06-06 Cangen International Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer
WO2008063655A2 (en) * 2006-11-20 2008-05-29 The Johns Hopkins University Dna methylation markers and methods of use
WO2012175562A2 (en) * 2011-06-21 2012-12-27 University Of Tartu Methylation and microrna markers of early-stage non-small cell lung cancer

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Data Sheet: Epigenetics; Infinium HumanMethylation450 BeadChip", 11 October 2012 (2012-10-11), XP055090635, Retrieved from the Internet <URL:http://res.illumina.com/documents/products/datasheets/datasheet_humanmethylation450.pdf> [retrieved on 20131128] *
A. VINCENT ET AL: "Genome-Wide Analysis of Promoter Methylation Associated with Gene Expression Profile in Pancreatic Adenocarcinoma", CLINICAL CANCER RESEARCH, vol. 17, no. 13, 24 May 2011 (2011-05-24), pages 4341 - 4354, XP055092899, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-10-3431 *
BROCK MALCOLM V ET AL: "DNA methylation markers and early recurrence in stage I lung cancer", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 358, no. 11, 13 March 2008 (2008-03-13), pages 1118 - 1128, XP002575979, ISSN: 1533-4406, DOI: 10.1056/NEJMOA0706550 *
HIROAKI HARADA ET AL: "Methylation of breast cancer susceptibility gene 1 ( BRCA1 ) predicts recurrence in patients with curatively resected stage I non-small cell lung cancer", CANCER, vol. 119, no. 4, 15 February 2013 (2013-02-15), pages 792 - 798, XP055092544, ISSN: 0008-543X, DOI: 10.1002/cncr.27754 *
KAIE LOKK ET AL: "Methylation Markers of Early-Stage Non-Small Cell Lung Cancer", PLOS ONE, vol. 7, no. 6, 29 June 2012 (2012-06-29), pages e39813, XP055092487, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0039813 *
KAZUAKI MIYAMOTO ET AL: "Identification of 20 genes aberrantly methylated in human breast cancers", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 116, no. 3, 1 September 2005 (2005-09-01), pages 407 - 414, XP002711967, ISSN: 0020-7136, [retrieved on 20050407], DOI: 10.1002/IJC.21054 *
MARINA BIBIKOVA ET AL: "High density DNA methylation array with single CpG site resolution", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 98, no. 4, 26 July 2011 (2011-07-26), pages 288 - 295, XP028304083, ISSN: 0888-7543, [retrieved on 20110802], DOI: 10.1016/J.YGENO.2011.07.007 *
ROMAICA A OMARUDDIN ET AL: "Detection of genomic DNA methylation with denaturing high performance liquid chromatography", HUMAN CELL, vol. 23, no. 2, 1 May 2010 (2010-05-01), pages 41 - 49, XP055126630, ISSN: 0914-7470, DOI: 10.1111/j.1749-0774.2010.00084.x *
SANDOVAL JUAN ET AL: "A prognostic DNA methylation signature for stage I non-small-cell lung cancer.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 10 NOV 2013, vol. 31, no. 32, 10 November 2013 (2013-11-10), pages 4140 - 4147, XP008166049, ISSN: 1527-7755 *
YOSHINO ET AL: "Promoter hypermethylation of the p16 and Wif-1 genes as an independent prognostic marker in stage IA non-small cell lung cancers", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 35, no. 05, 15 September 2009 (2009-09-15), XP055092515, ISSN: 1019-6439, DOI: 10.3892/ijo_00000437 *

Also Published As

Publication number Publication date
WO2014173905A2 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
EP3699280A3 (en) Novel cas9 systems and methods of use
EP2796552A3 (en) Methods and apparatus for synthesizing nucleic acids
WO2014173905A3 (en) Methods and kits for prognosis of stage i nsclc by determining the methylation pattern of cpg dinucleotides
WO2014108810A3 (en) Sample preparation on a solid support
CA2812115C (en) Epigenetic markers of colorectal cancers and diagnostic methods using the same
EP3845640A3 (en) Modified tranposases for improved insertion sequence bias and increased dna input tolerence
NZ723570A (en) Compositions and methods for quantifying a nucleic acid sequence in a sample
WO2014116729A3 (en) Haplotying of hla loci with ultra-deep shotgun sequencing
CA2840149C (en) Methods and nucleic acids for determining the prognosis of a cancer subject
BR112018010681A2 (en) method for modifying a targeted site, nucleic acid-modifying enzyme complex, and, nucleic acid.
WO2011143659A3 (en) Nucleic acid isolation methods
WO2016048833A3 (en) Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
MX2021000210A (en) Methods and products for transfecting cells.
JP2016526529A5 (en)
EP4246144A3 (en) Compositions and methods for screening mutations in thyroid cancer
WO2017201102A8 (en) Method of improved sequencing by strand identification
EP3572529A3 (en) Gene methylation based colorectal cancer diagnosis
WO2013012440A3 (en) Methods and devices for dna sequencing and molecular diagnostics
MX2017001405A (en) Detection of target nucleic acids using hybridization.
WO2016109799A3 (en) Method of rna isolation from clinical samples
EP4219739A3 (en) Polymerase compositions, methods of making and using same
EP2977467A3 (en) Method, use of marker, and determination device for obtaining information on plural types of cancers
WO2011106541A3 (en) Diagnostic methods involving loss of heterozygosity
WO2018096375A3 (en) Determination of the receptive status of the endometrium
BR112014026440A8 (en) analysis, methods and apparatus for the evaluation of RNA disruption.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14722139

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14722139

Country of ref document: EP

Kind code of ref document: A2